AgomAb Therapeutics N.V. American Depositary Shares
AGMB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$368.87M
Close$
$1.96
73.9% downside
Current Fair Value
73.9% downsideOvervalued by 73.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $368.87 Million |
|---|---|
| Enterprise Value | $149.68 Million |
| Earnings per Share | $-1.28 |
| Beta | 1.8 |
| Outstanding Shares | 48,736,779 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -8.46 |
|---|---|
| PEG | -17.51 |
| Price to Sales | - |
| Price to Book Ratio | 1.5 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.38
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
$-0.95
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 53.26%▲ 5.34% |
|---|---|
| Total Invested | $336.96M▲ 37.37% |
| Investors Holding | 34▲ 2.00% |
About AgomAb Therapeutics N.V. American Depositary Shares
57 employees
CEO: Tim Knotnerus
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's ...